Published 24 February 2022

The National Institute for Health and Care Excellence (NICE) has today confirmed it's recommendation for the PARP inhibitor niraparib as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.

It is recommended if someone has a BRCA mutation and has had two courses of platinum-based chemotherapy, or if they do not have a BRCA mutation and have had 2 or more courses of platinum-based chemotherapy, and their disease has responded to the most recent platinum treatment.

Previously niraparib was only available in these circumstances through the Cancer Drugs Fund. Today's announcement means it can now be routinely prescribed.

Read more here


If you have any questions about this news and how it might affect you or a loved one, please call the Ovacome support line on 0800 008 7054 or email [email protected] .